Delving into the Latest Updates on Shanxi Kangbao Biological Product Co. Ltd. with Synapse

Overview

Tags

Other Diseases

Infectious Diseases

Hemic and Lymphatic Diseases

Small molecule drug

Non-recombinant coagulation factor

Fusion protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	4
Hemic and Lymphatic Diseases	3
Immune System Diseases	2
Neoplasms	1

Top 5 Drug Type	Count

Non-recombinant coagulation factor	3
Small molecule drug	3
Interferons	1
Fusion protein	1
Prophylactic vaccine	1

Top 5 Target	Count

gp41(Transmembrane glycoprotein gp41)	2
IFNAR(Interferon alpha/beta receptor)	1
factor IX(Coagulation factor IX)	1
F10(Coagulation factor X)	1
Fibrinogen	1

主要目的：（1）评价康宝人纤维蛋白原在先天性纤维蛋白原减少或缺乏症患者中单次用药的药代动力学特征；（2）评价康宝人纤维蛋白原治疗先天性纤维蛋白原减少或缺乏症患者出血事件的有效性。次要目的：（1）评价康宝人纤维蛋白原治疗先天性纤维蛋白原减少或缺乏症患者出血事件的安全性；（2）评价已上市同类产品在先天性纤维蛋白原减少或缺乏症患者中单次用药的药代动力学特征。

[Translation]

Primary objectives: (1) To evaluate the pharmacokinetic characteristics of a single dose of Conbo human fibrinogen in patients with congenital fibrinogen deficiency or deficiency; (2) To evaluate the effectiveness of Conbo human fibrinogen in treating bleeding events in patients with congenital fibrinogen deficiency or deficiency. Secondary objectives: (1) To evaluate the safety of Conbo human fibrinogen in treating bleeding events in patients with congenital fibrinogen deficiency or deficiency; (2) To evaluate the pharmacokinetic characteristics of a single dose of similar products already on the market in patients with congenital fibrinogen deficiency or deficiency.

Start Date26 Dec 2024

Sponsor / Collaborator

Shanxi Kangbao Biological Product Co. Ltd.

NCT06560489

/ Enrolling by invitationPhase 1/2

Clinical Trial of Safety, Pharmacodynamics and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Primary Treatment of HIV-infected Patients

A Randomized, Double-Blind, Parallel-Group, Exploratory Clinical Study to Evaluate the Safety, Pharmacodynamic Effects, and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Treatment-Naive HIV-Infected Individuals

Start Date02 Sep 2024

Sponsor / Collaborator

Shanxi Kangbao Biological Product Co. Ltd.

[+1]

CTR20243081

/ RecruitingPhase 2

在未接受过抗病毒治疗的HIV感染者中评估LP-98多次皮下注射的安全性、药效作用和药代动力学特征的随机、双盲、平行设计的探索性临床研究

[Translation] A randomized, double-blind, parallel-design exploratory clinical study to evaluate the safety, pharmacodynamics and pharmacokinetic characteristics of multiple subcutaneous injections of LP-98 in HIV-infected patients who have not received antiviral treatment

主要目的：评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的安全性和耐受性。次要目的：评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的药效（PD）作用。评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的药代动力学（PK）特征。评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的免疫原性。探索性目的：探索在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的病毒学治疗失败的情况。

[Translation]

Primary objective: To evaluate the safety and tolerability of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. Secondary objectives: To evaluate the pharmacodynamic (PD) effect of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. To evaluate the pharmacokinetic (PK) characteristics of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. To evaluate the immunogenicity of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. Exploratory objectives: To explore the failure of virological treatment after multiple subcutaneous injections of LP-98 in HIV-infected individuals who have not received antiviral treatment.

Start Date28 Aug 2024

Sponsor / Collaborator

Institute of Pathogen Biology Chinese Academy of Medical Sciences

[+1]

100 Clinical Results associated with Shanxi Kangbao Biological Product Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Shanxi Kangbao Biological Product Co. Ltd.

Login to view more data

28

Literatures (Medical) associated with Shanxi Kangbao Biological Product Co. Ltd.

Shanxi Yike Daxue Xuebao

Compatible stability of safflower injection in two different infusions

Author: Wang, Zonggang ; He, Lijuan ; Zhang, Huilan ; Shen, Yunfei ; Chen, Tongwei ; Huo, Jianfu

A method was established for determining the contents of hydroxysafflor yellow A, and the stability and compatibility of safflower injection in 0.9% sodium chloride injection or 5% glucose injection were explored.At 0, 2, 4, 6, 8, and 24 h, the contents of hydroxysafflor yellow A in two mixtures of safflower injection and 0.9% sodium chloride injection or 5% glucose injection were determined by HPLC, and the pH value and microparticles were also investigated.There was no significant change in the pH value and contents of hydroxysafflor yellow A in 24 h at room temperature (25°) after compatibility.However microparticles had significant changes, and increased with the increase of dose and time.The stability is good within 4 h in two different infusions of safflower injection.

Huaxue Yu Shengwu Gongcheng

Determination of pamidronate disodium content by HPLC

Author: Huo, Jian-fu ; Lu, Zhi-hong

The content of pamidronate disodium was determined by HPLC.The HPLC conditions were as follows: the mobile phase of acetonitrile -0.4% EDTA disodium sodium hydroxide solution (15:85), the fluorescence detector with excitation wavelength of 395 nm and emission wavelength of 480 nm, the flow rate of 1.0 mL · min^-1, the injection volume of 10 μL.Results showed that, the quantification limit of pamidronate disodium was 5 ng and its detection limit was 2.5 ng, the RSD of precision experiment was less than 1.0%.The concentration had good linear relationship with peak area within the range of 2.03-20.3 μg · mL^-1.This method can determine the content of pamidronate disodium rapidly and accurately with high repeatability and good stability.

Zhonghua Zhongliu Fangzhi Zazhi

Anti-cancer effect of rhVEGF_121KDR/rGEL fusion toxin

Author: Shen, Yun-fei ; Zhang, Li ; Zhou, Man-xiang ; Wu, Fu-jun ; Tang, Xue-ling ; Zhang, Zhan-li ; Jiang, Qian ; Sun, Hong-yan

The anti-cancer effects and the tumor-targeting of rhVEGF_121KDR/rGEL fusion toxin in human tumor xenografts models were investigated for the development of more effective and safer anticancer drugs.Human carcinoma xenografts models of hepatoma SMMC-7721 cells, esophageal carcinoma KYSE-150 cells, gastric carcinoma SGC-7901 cells and colon carcinoma HT-29 cells were established, tumor volume was measured every 2-3 days after administration, tumor growth curve was drawn, and the relative tumor growth rate was calculatedThe localization of fusion toxin in tumor tissues was examined by immunohistochem.The volume of human carcinoma xenografts of SMMC-7721, KYSE-150, SGC-7901 and HT-29 was resp. (89.33 ± 56.36) mm³, (142.47 ± 58.67) mm³, (73.80 ± 31.05) mm³ and (79.64 ± 34.46) mm³ in the treated group, and (328.19 ± 200.27) mm³, (474.05 ± 167.42) mm³, (172.34 ± 41.78) mm³ and (480.26 ± 348.34) mm³ in the untreated group.The relative tumor volume (RTV) of the four human carcinoma xenografts in the treated group was resp. 5.31 ± 2.13, 5.72 ± 2.45, 3.59 ± 1.55 and 5.82 ± 1.92, and in untreated group, the RTV was resp. 17.10 ± 6.00, 23.71 ± 10.36, 11.65 ± 4.14 and 23.24 ± 5.74.The relative growth rate was resp. 31.05%, 24.12%, 25.04% and 30.82%.Both tumor volume and RTV of human carcinoma xenografts treated with the fusion toxin demonstrated significant reduction compared with untreated controls (all P < 0.01).In conclusion, the rhVEGF_121KDR/rGEL could significantly inhibit tumor growth in at least four xenograft models, and was a promising candidate drug for the targeted therapy of cancer.

100 Deals associated with Shanxi Kangbao Biological Product Co. Ltd.

Login to view more data

100 Translational Medicine associated with Shanxi Kangbao Biological Product Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

1

3

Phase 1 Clinical

Phase 2 Clinical

2

3

Approved

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Human Prothrombin Complex Concentrate(Shanxi Kangbao Biological Products) ( factor IX )	Hemophilia B More	Approved
Factor VIII(Shanxi Kangbao Biological Products) ( F10 )	Hemophilia A More	Approved
Human fibrinogen (Shanxi Kangbao Biological Product Co. Ltd.) ( Fibrinogen )	Afibrinogenemia More	Approved
LP-98 ( gp41 )	HIV Infections More	Phase 2
Lipovirtide ( gp41 )	HIV Infections More	Phase 2